Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

By M. Boolell, M. J. Allen, Ballard Sa, S. Gepi-Attee, Muirhead Gj, Naylor Am, Osterloh Ih, C. Gingell. 1996

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery (2013, neutral): “comparison to de novo design[4-11].”
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond (2006, background): “By 1997 more than 4,500 subjects had been exposed to sildenafil, and 21 separate clinical trials had demonstrated the efficacy of sildenafil in various patient populations [16] [17] [18] [19] [20] [21] .”
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use (2006, unknown): “(1986) Boolell et al. (1996) Bischoff et al.”
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. (2006, background): “Surprisingly and interestingly, clinical study reveals that 1 compound, sildenafil, would be beneficial for male erectile dysfunction (ED), and therefore, sildenafil was developed and marketed as Viagrai by Pfizer (IC50=3.9 nM; Boolell et al., 1996).”